Stephen Leshe, who has held numerous roles in medical device sales over his 30-year career, is one of four new regional Vice Presidents of Sales at CoreLink LLC. Leshe’s career has included distribution for early stage medical technologies as well as established spine companies. CoreLink, based in St. Louis, Missouri, says that it is expanding due to aggressive investments in new product development and a commitment to its surgeon and distributor partners.
Stephen Leshe: New Regional Vice President of Sales at CoreLink
1 min read Premium comments
Secondary#corelink#stephenleshe
“I understand the challenges that face independent medical device distributors. My experience in strategic sales and marketing, contracting, negotiations, operations, intellectual property, and compliance will serve me well in this new role,” said Leshe.
“Steve ran a multi-state, highly successful independent distributorship; he uniquely understands the challenges that face independent medical device distributors in the rapidly evolving medical device space. His experience in strategic sales and marketing, contracting, negotiations, operations, intellectual property, and compliance will serve CoreLink well in our growth objectives,” said Derek Kuyper, vice president of CoreLink.
Leshe commented to OTW, “I am looking most forward to partnering with our distribution team and surgeons to implement our technologies in order to help improve patient outcomes.”
“While the COVID pandemic has lowered elective case volume across the industry, CoreLink has invested in new product development, strengthened internal processes, and continued to rapidly grow customers. We believe expanding our Sales Management Team during this time is a great opportunity to increase market share in a rapidly evolving market,” said Derek Kuyper.
The company anticipates several product launches over the next few months.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.